Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | DKK1 | O94907 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23578784 | 1.00 | EGFR (0.44) | EGFRKDM1APDE4DDYRK1AHRH3 | |
| SCHEMBL30848738 | 0.93 | EGFR (0.44) | EGFRKDM1APDE4DDYRK1AHRH3 | |
| SCHEMBL29958987 | 0.91 | EGFR (0.50) | EGFRKDM1APDE4DDYRK1AHRH3 | |
| SCHEMBL22464585 | 0.91 | EGFR (0.50) | EGFRKDM1APDE4DDYRK1AHRH3 | |
| SCHEMBL30733190 | 0.91 | EGFR (0.50) | EGFRKDM1APDE4DDYRK1AHRH3 | |
| SCHEMBL16374375 | 0.91 | EGFR (0.50) | EGFRKDM1APDE4DDYRK1AHRH3 | |
| SCHEMBL19015477 | 0.91 | EGFR (0.50) | EGFRKDM1APDE4DDYRK1AHRH3 | |
| SCHEMBL15740731 | 0.91 | EGFR (0.50) | EGFRKDM1APDE4DDYRK1AHRH3 | |
| SCHEMBL15740505 | 0.91 | EGFR (0.50) | EGFRKDM1APDE4DDYRK1AHRH3 | |
| SCHEMBL29958815 | 0.91 | EGFR (0.50) | EGFRKDM1APDE4DDYRK1AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115135642-B | Inhibitors of EGFR mutant forms | 缆图药品公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-117916232-A | Heterocyclic EGFR inhibitors for the treatment of cancer | 缆图药品公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117858872-A | Heterocyclic EGFR inhibitors for the treatment of cancer | 缆图药品公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2022271612-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022271749-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | disclosed |
| CN-115135642-A | Inhibitors of mutant forms of EGFR | 缆图药品公司 | 2022-09-30 | — | — | CN | disclosed |